Shanghai Kaibao Pharmaceutical (300039) — Tangible Net Worth Ratio
Shanghai Kaibao Pharmaceutical (300039) has a Tangible Net Worth Ratio of 96.2% as of June 2026. This metric is calculated by deducting intangible assets (CN¥160.97 Million) from net assets (CN¥4.29 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Also explore 300039 year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Shanghai Kaibao Pharmaceutical Tangible Net Worth Ratio (2006–2025)
This chart shows how Shanghai Kaibao Pharmaceutical's Tangible Net Worth Ratio has changed across 20 annual periods from 2006 to 2025. As of June 2026, the ratio stands at 96.2%, reflecting net assets of CN¥4.29 Billion with intangible assets of CN¥160.97 Million CNY. For live market cap and overall valuation, see 300039 company net worth.
Annual Tangible Net Worth Ratio for Shanghai Kaibao Pharmaceutical (2006–2025)
The table below presents the year-by-year Tangible Net Worth Ratio for Shanghai Kaibao Pharmaceutical from 2006 to 2025, covering 20 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. Explore 300039 capex to operating cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 96.3% | CN¥4.42 Billion | CN¥163.57 Million | CN¥4.78 Billion | ▲ +0.4 pp |
| 2024 | 95.9% | CN¥4.10 Billion | CN¥168.80 Million | CN¥4.52 Billion | ▼ -3.0 pp |
| 2023 | 98.9% | CN¥4.03 Billion | CN¥45.11 Million | CN¥4.58 Billion | ▲ +0.1 pp |
| 2022 | 98.8% | CN¥3.76 Billion | CN¥44.23 Million | CN¥4.26 Billion | ▲ +0.2 pp |
| 2021 | 98.6% | CN¥3.04 Billion | CN¥42.90 Million | CN¥3.36 Billion | ▲ +0.3 pp |
| 2020 | 98.2% | CN¥2.58 Billion | CN¥45.26 Million | CN¥2.88 Billion | ▼ -0.1 pp |
| 2019 | 98.4% | CN¥2.57 Billion | CN¥41.33 Million | CN¥2.84 Billion | ▲ +0.1 pp |
| 2018 | 98.3% | CN¥2.49 Billion | CN¥42.12 Million | CN¥2.75 Billion | ▲ +0.2 pp |
| 2017 | 98.2% | CN¥2.37 Billion | CN¥43.75 Million | CN¥2.68 Billion | ▲ +0.2 pp |
| 2016 | 97.9% | CN¥2.20 Billion | CN¥45.38 Million | CN¥2.53 Billion | ▲ +0.3 pp |
| 2015 | 97.7% | CN¥2.01 Billion | CN¥46.79 Million | CN¥2.43 Billion | ▲ +0.2 pp |
| 2014 | 97.5% | CN¥1.88 Billion | CN¥47.12 Million | CN¥2.12 Billion | ▲ +0.1 pp |
| 2013 | 97.4% | CN¥1.61 Billion | CN¥42.30 Million | CN¥1.77 Billion | ▼ -0.8 pp |
| 2012 | 98.2% | CN¥1.42 Billion | CN¥25.86 Million | CN¥1.56 Billion | ▲ +0.2 pp |
| 2011 | 98.0% | CN¥1.33 Billion | CN¥26.48 Million | CN¥1.45 Billion | ▲ +0.2 pp |
| 2010 | 97.8% | CN¥1.24 Billion | CN¥27.12 Million | CN¥1.37 Billion | ▲ +0.2 pp |
| 2009 | 97.6% | CN¥1.15 Billion | CN¥27.80 Million | CN¥1.35 Billion | ▲ +0.2 pp |
| 2008 | 97.4% | CN¥126.92 Million | CN¥3.32 Million | CN¥229.88 Million | ▼ -1.4 pp |
| 2007 | 98.7% | CN¥76.96 Million | CN¥965.65K | CN¥161.61 Million | ▲ +2.3 pp |
| 2006 | 96.4% | CN¥37.24 Million | CN¥1.32 Million | CN¥109.03 Million | — |